Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.37 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 5/20 | 0.36 |
| ▸ | MERTK | Q12866 | 5/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.34 |
| ▸ | MELK | Q14680 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15420531 | 0.91 | SYK (0.39) | MAPK8MAPK9MAPK10AXLMERTK | |
| SCHEMBL15420023 | 0.89 | GRM5 (0.35) | CYP46A1KCNH2GPR119MAPK8MAPK9 | |
| SCHEMBL15420309 | 0.87 | CYP46A1 (0.38) | CYP46A1MAPK8MAPK9MAPK10CHRM1 | |
| SCHEMBL12989171 | 0.86 | CHRM1 (0.40) | CYP46A1AXLMERTKCHRM1RIPK2 | |
| SCHEMBL15420585 | 0.86 | CHRM1 (0.40) | CYP46A1AXLMERTKCHRM1RIPK2 | |
| SCHEMBL12989178 | 0.86 | CHRM1 (0.40) | CYP46A1AXLMERTKCHRM1RIPK2 | |
| SCHEMBL15420551 | 0.86 | CYP46A1 (0.33) | CYP46A1KCNH2GPR119MAPK8MAPK9 | |
| SCHEMBL15420692 | 0.86 | CYP46A1 (0.33) | CYP46A1KCNH2GPR119MAPK8MAPK9 | |
| SCHEMBL12990033 | 0.86 | CYP46A1 (0.33) | CYP46A1KCNH2GPR119MAPK8MAPK9 | |
| SCHEMBL15420479 | 0.85 | CYP46A1 (0.38) | CYP46A1MAPK8MAPK9MAPK10CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694472-B1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2020-03-11 | — | — | EP | disclosed |
| US-9527807-B2 | Sulfonamide derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024650-A1 | SULFONAMIDE DERIVATIVE AND USE THEREOF | GRIN2A, GRIN2B, SLC1A2 | CYP46A1 1863/4885KCNH2 2363/4885GPR119 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.